Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinical trials with glimepiride.

C M Clark1, A W Helmy

  • 1Regenstrief Institute for Health Care, Richard L. Roudebush Veterans Affairs Medical Center and the Indiana University School of Medicine, Indianapolis, Indiana 46202, USA.

Drugs of Today (Barcelona, Spain : 1998)
|March 11, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A review of domestic land use change attributable to U.S. biofuel policy.

Renewable & sustainable energy reviews·2023
Same author

Modeled Vegetation Community Trajectories: Effects from Climate Change, Atmospheric Nitrogen Deposition, and Soil Acidification Recovery.

Environmental advances·2023
Same author

The impact of air pollution on terrestrial managed and natural vegetation.

Philosophical transactions. Series A, Mathematical, physical, and engineering sciences·2020
Same author

Threshold effects of air pollution and climate change on understory plant communities at forested sites in the eastern United States.

Environmental pollution (Barking, Essex : 1987)·2020
Same author

Feasibility of coupled empirical and dynamic modeling to assess climate change and air pollution impacts on temperate forest vegetation of the eastern United States.

Environmental pollution (Barking, Essex : 1987)·2017
Same author

Enlarged vestibular aqueducts and other inner-ear abnormalities in patients with Down syndrome.

The Journal of laryngology and otology·2016
Same journal

Monoclonal antibodies for treatment of osteoporosis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Mitapivat for sickle cell disease and thalassemia.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Cenegermin for the treatment of dry eye disease.

Drugs of today (Barcelona, Spain : 1998)·2023
See all related articles

Glimepiride is an effective and safe oral diabetes medication, comparable to other sulfonylureas but with a potentially superior safety profile. It offers rapid action and can be used with insulin for better glycemic control.

Area of Science:

  • Pharmacology
  • Endocrinology
  • Diabetes Mellitus Treatment

Background:

  • Glimepiride is a third-generation sulfonylurea used for type 2 diabetes.
  • Understanding its efficacy and safety compared to other agents is crucial for clinical practice.

Purpose of the Study:

  • To review data on glimepiride's efficacy, safety, and pharmacologic properties.
  • To compare glimepiride with other oral hypoglycemic agents and insulin.

Main Methods:

  • Review of 21 placebo-controlled, active-controlled, or noncomparative studies.
  • Inclusion of over 6500 patients, with more than 4220 treated with glimepiride.

Main Results:

  • Glimepiride demonstrates rapid onset of action and efficacy at a single daily dose.

Related Experiment Videos

  • It is equally effective as other second-generation sulfonylureas (1-8 mg/day) and shows a superior safety profile at lower doses.
  • Glimepiride is safe and effective in combination with insulin.

    • Conclusions:

    • Glimepiride offers comparable efficacy to other sulfonylureas with a potentially better safety profile.
    • Its unique pharmacologic properties may offer theoretical advantages, though clinical significance is yet to be established.
    • Glimepiride is a valuable option for managing type 2 diabetes, alone or with insulin.